SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (1694)9/19/2000 8:11:08 AM
From: rkrw  Respond to of 52153
 
<<<Does my read on where they are going make sense?>>>

The Pseudomonas aeruginosa project is a long way from even entering the clinic. I think its preliminary to attach any value to it.
The crux of itmn at this point is actimmune, actimmune, actimmune. Expand its use, expand the market cap.



To: IRWIN JAMES FRANKEL who wrote (1694)9/19/2000 9:21:56 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 52153
 
>> Does my read on where they are going make sense? <<

Nope. They won't look to use IFN in CF, IMO. Yes, you're looking at a good patient population for an effective anti-Pseudomonas MAb, but..... maybe I'm a bit close to the subject........ but...... tough project, and finding patients for Pseudomonas clinicals always seems to be a bit tougher than postulated.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News